Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (645)	2/17/2000 3:42:00 PM
From: Harold Engstrom	Read Replies (2) \| Respond to of 52153

I read that Eisinger article and pretty much viewed it in the same light as TSC articles on SEPR over the past year - not accurate. Guess Eisinger could shake TSC methodologies when coming over to WSJ. ELN has done well over the past couple of weeks (what hasn't?), but my attraction is based on its growth rate, earnings, good fundementals and seemingly good vision. It seems to have a limited downside and there aren't too many stocks like that around right now.